Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

This is a clinical study aiming to assess pharmacokinetics, pharmacodynamics and preliminary efficacy of ZE46-0134 in patients with FLT3 and spliceosome mutated Relapsed or Refractory Acute Myeloid Leukemia

Participants needed: 150
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Lomond Therapeutics Holdings, Inc.Updated: Dec 31, 2025Locations: 23
Eligibility criteria

Written Informed Consent must be obtained from the patient or legally authorized... [+11]

Written Informed Consent must be obtained from the patient or legally authorized... [+23]

Read more
Status: Not yet recruiting

A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients

This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory Acute Myeloid Leukemia patients.

Participants needed: 66
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Lomond Therapeutics Holdings, Inc.Updated: Dec 26, 2025
Eligibility criteria

Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN), alanine am... [+2]

Isolated myeloid sarcoma (meaning, patients must have blood or marrow involvemen... [+27]

Read more
Status: Recruiting

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low-grad lymphomas.

Participants needed: 66
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Lomond Therapeutics Holdings, Inc.Updated: Dec 5, 2025Locations: 4
Eligibility criteria

Men and women aged ≥18 years. [+8]

FOR PART 2 ONLY [+15]

Read more